secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001808805-21-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology Q2 2021 net loss of $10.7M; raised $345.5M in business combination
--------------------------------------------------------------------------------

- Completed business combination with ARYA Sciences, receiving gross proceeds of $345.5M.
- Q2 2021 operating expenses $10.7M (up 215% YoY); net loss $10.7M vs $3.4M in Q2 2020.
- Cash and investments $388.4M as of June 30, 2021.
- Appointed Emma Lundberg, Ph.D. to Scientific Advisory Board.
- Planning platform commercialization in late-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880521000004/0001808805-21-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880521000004/naut-20210810.htm
  HTML page:      https://secwatch.observer/filing/0001808805-21-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer